Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study

Authors
Category Primary study
JournalDermatology and Therapy
Year 2022
This article has no abstract
Epistemonikos ID: b92900340887dd6327f5620f9373d16da3ac4b58
First added on: Feb 14, 2025